Fusion Pharmaceuticals Inc (FUSN)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
21.55 +0.03 (+0.14%) 06/03/24 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 21.55 unch (unch) -
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -94,897 | -87,612 | -81,047 | -78,333 | -16,189 |
| Depreciation Amortization | 1,345 | 909 | 634 | 482 | 290 |
| Income taxes - deferred | 845 | -3,162 | -991 | -576 | -59 |
| Accounts receivable | 54 | 296 | -357 | N/A | N/A |
| Accounts payable and accrued liabilities | -721 | 400 | -1,183 | 2,558 | 479 |
| Other Working Capital | -1,317 | 3,660 | -14,595 | 5,736 | 3,085 |
| Other Operating Activity | 12,889 | 12,233 | 21,799 | 40,366 | -1,296 |
| Operating Cash Flow | $-81,802 | $-73,276 | $-75,740 | $-29,767 | $-13,690 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3,890 | -2,142 | -1,491 | -1,123 | -456 |
| Purchase Of Investment | -230,570 | -165,156 | -172,469 | -219,030 | N/A |
| Sale Of Investment | 191,697 | 190,385 | 211,734 | 9,700 | N/A |
| Investing Cash Flow | $-42,763 | $23,087 | $37,774 | $-210,453 | $-456 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 34,693 | N/A | N/A | N/A |
| Common Stock Issued | 146,037 | 6,040 | 622 | 197,681 | N/A |
| Other Financing Activity | -4,031 | 0 | -275 | 67,826 | 52,187 |
| Financing Cash Flow | $142,006 | $40,733 | $347 | $265,507 | $52,187 |
| Beginning Cash Position | 45,333 | 54,789 | 92,408 | 67,121 | 29,080 |
| End Cash Position | 62,774 | 45,333 | 54,789 | 92,408 | 67,121 |
| Net Cash Flow | $17,441 | $-9,456 | $-37,619 | $25,287 | $38,041 |
| Free Cash Flow | |||||
| Operating Cash Flow | -81,802 | -73,276 | -75,740 | -29,767 | -13,690 |
| Capital Expenditure | -3,890 | -2,142 | -1,491 | -1,123 | -456 |
| Free Cash Flow | -85,692 | -75,418 | -77,231 | -30,890 | -14,146 |